Exciting News for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency ~ Event Coming in May

Agios Announces FDA Approval of PYRUKYND (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

An exciting new event surrounding this announcement is in the works for May of 2022! Stay tuned!

See attachments for more info prior to the event.

PYRUKYND Approval PR_02.17.2022.pdf

Download PDF • 269KB

PYRUKYND Label.pdf

Download PDF • 322KB